Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Viral infection drives tissue fibrosis in vitro

Andrea P. Malizia, Dermot Walls, Jim J. Egan, Peter P. Doran
European Respiratory Review 2008 17: 49-50; DOI: 10.1183/09059180.00010707
Andrea P. Malizia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dermot Walls
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim J. Egan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter P. Doran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a refractory and lethal interstitial lung disease characterized by loss of alveolar epithelial cells, fibroblast proliferation and extra-cellular matrix protein deposition. EBV, localised to alveolar epithelial cells of pulmonary fibrosis patients is associated with a poor prognosis.

In this study we utilised a microarray-based differential gene expression analysis strategy to identify molecular drivers of EBV associated with lung fibrosis. A549 cells and an alveolar epithelial cell line infected with EBV (VAAK) were used to identify genes whose expression was altered by EBV reactivation.

EBV reactivation by TGFbeta1 drives alterations in expression of non-canonical Wnt pathway mediators, implicating it in epithelial mesenchymal transition (EMT), the molecular event underpinning scar production in tissue fibrosis. Cell invasion, EMT correlated transcripts expression, GSK-3b and c-Jun activation were altered in response to non-canonical Wnt pathway regulation. The role of EBV in promoting fibrosis can be attenuated by antiviral strategies and inhibition of Wnt signalling.

Activation of non-canonical Wnt signalling pathway by EBV in epithelial cells suggests a novel mechanism of tissue fibrosis. These data present a framework for further description of the link between infectious agents and fibrosis, a significant disease burden.

MY JOB AND THE UNIT IN WHICH I WORK

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

I am a research fellow working as part of the Advanced Lung Disease and Lung Transplant Programme at Mater Misericordiae University Hospital, University College Dublin (Dublin, Ireland). From 2006, I have been funded by the National Heart and Lung Transplant Programme to work on the molecular mechanisms underlying the effect of Epstein–Barr virus (EBV) infection in idiopathic pulmonary fibrosis (IPF) development. I am currently supervised by Dr Jim Egan and Dr Peter Doran, and am pursuing my PhD degree at the Genome Resource Unit, a collaborative and interdepartmental research initiative at the University College Dublin, focusing on translational lung research.

MY WINNING POSTER AS PART OF MY RESEARCH

After gaining a BSc in 2004, I started to work in the Genome Resource Unit, University College Dublin. In 2006, I started a PhD programme with Dr Doran, studying the molecular aspects underpinning Herpesviridae infection in IPF, and their association with poor prognosis. A collaborative contract with Dr Egan as research fellow gave me the possibility to study the molecular aspect of IPF through a translational and clinical approach.

This joint collaboration produced important data about the key role of EBV in alveolar epithelial cell biology. In a collaborative study with Dr Dominic Keating, we identified genes whose expression were significantly altered in alveolar epithelial cells (A549) in response to transforming growth factor (TGF)-β1, interleukin (IL)-4 and -13 and EBV by using microarray and computational biology strategies. A pool of extracellular matrix (ECM) proteins or modulators of matrix turnover was curated via Onto-Compare and Gene-Ontology databases for baited cluster analysis of ECM associated genes. Of this grouping, members of the ADAM (A Disintegrin And Metalloproteinase domain-containing) family of genes were differentially expressed. ADAM gene expression was also identified in EBV infected A549 cells, as well as IL-13- and -4-stimulated cells, suggesting a potential role of EBV in ECM accumulation in IPF [1].

To determine the role of host predisposition in IPF development, we utilised transgenic mice to simulate TGF-β1-related genetic predisposition to external stimuli, rather than a tissue-specific TGF-β1 transgenic model. We defined the fibrotic response in the transgenic animal population following epithelial cell injury, and characterised the transcriptomic changes in response to belomycin-induced injury. The double-injury mice were characterised by molecular patterns that are hallmarks of fibrosis, including ECM and cell growth, and regulation gene clusters. Further investigations will focus on characterising the combination of these factors in patients with IPF, with attention specifically paid to the role of the TGF-β1 gene as a prime for subsequent lung injury [2].

Based on contradictory findings of the role of TGF-β1 in EBV-infected and noninfected epithelial cells [3, 4], my main research project is based on investigating EBV lytic phase induction mechanism by TGF-β1 and chemical compounds to study molecular virus–host interactions in alveolar epithelial cells.

MY RESEARCH AS PART OF MY WORKING GROUP/RESEARCH TEAM

The Translational Research Programme in Advanced Lung Disease, based at the Genome Resource Unit and Mater Misericordiae Hospital, is led by Dr Egan and Dr Doran, and includes Dr Keating and Dr Rauf Ahsan. Dr Egan is also a Consultant Respiratory Physician at the National Centre for Cardiothoracic Transplant. His research interests include chronic and acute lung diseases, with particular emphasis on interstitial lung diseases. Dr Doran is a lecturer at the University College Dublin, School of Medicine and Medical Science, and Director of the Genome Resource Unit. His research interests include the identification of the mechanisms of disease using gene discovery strategies. Furthermore, he has driven the creation of informatics solutions for the integration of clinical and biological data in human disease research. Dr Keating is a medical doctor who investigated IPF in pulmonary tissue samples ex vivo from transplanted lung. He had a major role in developing a stable, EBV-infected, alveolar epithelial cell line in collaboration with Dr Dermot Walls at the Dublin City University. Dr Ashsan is a surgeon who has collaborated in the study of IPF by using a primary human, small-airway, epithelial cell-based method to investigate their transcript expression associated with epithelial mesenchymal transition in response to TGF-β1.

THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE

IPF is a common interstitial lung disease of unknown aetiology. Clinical deterioration in IPF is expected, and 5-yr survival ranges from 30–50%. Despite improvements in the diagnostic approach to IPF and active research in recent years, the molecular mechanisms of the disease remain poorly understood. This highly lethal lung disorder continues to pose major clinical challenges, since an effective therapeutic regimen has yet to be identified and developed.

Our research is supported by the observation that alveolar epithelial cell injury and repair is an important trigger event in the development of lung fibrosis. Using Epstein–Barr virus-infected alveolar epithelial cells, we have characterised the genomic alterations in these cells in association with an Epstein–Barr virus lytic phase status. The microarray approach we have described in the abstract uncovered the Wnt pathway as being a novel signalling in which transcripts are highly expressed in Epstein–Barr virus-infected cells in response to transforming growth factor-β1. The identification and characterisation of novel profibrotic mediators will have an impact on their use as possible therapeutic targets. Since no effective therapeutic options for patients with idiopathic pulmonary fibrosis exist at this moment, future work by our group and others will unravel the regulation of Epstein–Barr virus reactivation as a pro-fibrotic factor, and this may open up new therapeutic options for patients with idiopathic pulmonary fibrosis.

Cell and Molecular Biology Young Scientist Travel Award, sponsored by AstraZeneca

STATEMENT OF INTEREST

None declared.

    • © ERSJ Ltd

    References

    1. ↵
      Keating DT, Sadlier D, Patricelli A, et al. Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells. Respir Res 2006; 7: 114
      OpenUrlCrossRefPubMed
    2. ↵
      Haider Y, Malizia AP, Keating DT, et al. Host predisposition by endogenous transforming growth factor-beta1 overexpression promotes pulmonary fibrosis following bleomycin injury. J Inflamm 2007; 4: 18
      OpenUrlCrossRef
    3. ↵
      Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol 1992; 119: 1017–1021.
      OpenUrlFREE Full Text
    4. ↵
      Fukuda M, Ikuta K, Yanagihara K, et al. Effect of transforming growth factor-beta1 on the cell growth and Epstein–Barr virus reactivation in EBV-infected epithelial cell lines. Virology 2001; 288: 109–118.
      OpenUrlCrossRefPubMed
    PreviousNext
    Back to top
    View this article with LENS
    Vol 17 Issue 107 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Viral infection drives tissue fibrosis in vitro
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Viral infection drives tissue fibrosis in vitro
    Andrea P. Malizia, Dermot Walls, Jim J. Egan, Peter P. Doran
    European Respiratory Review Apr 2008, 17 (107) 49-50; DOI: 10.1183/09059180.00010707

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Viral infection drives tissue fibrosis in vitro
    Andrea P. Malizia, Dermot Walls, Jim J. Egan, Peter P. Doran
    European Respiratory Review Apr 2008, 17 (107) 49-50; DOI: 10.1183/09059180.00010707
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • MY JOB AND THE UNIT IN WHICH I WORK
      • MY WINNING POSTER AS PART OF MY RESEARCH
      • MY RESEARCH AS PART OF MY WORKING GROUP/RESEARCH TEAM
      • THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE
      • STATEMENT OF INTEREST
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Implications and priorities of tobacco control in Belgium and Europe
    • The psychobiology of nicotine dependence
    • Smoking and impact on health
    Show more Original Articles

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERR

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising
    • Sponsorship

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 0905-9180
    Online ISSN: 1600-0617

    Copyright © 2022 by the European Respiratory Society